A new report from Americans for Tax Fairness concludes:
“In addition to dodging its fair share of taxes, Pfizer—maker of Celebrex, Lipitor, Lyrica, and Viagra, among many other health-care products—has also been aggressively raising prescription drug prices, thereby straining patients and our health care system and in some cases putting needed medications out of reach.
By dodging taxes while boosting prescription drug prices, Pfizer squeezes American families and communities from two sides at once. In the company’s biggest insult to America yet, Pfizer’s merger will allow it to go on enjoying all the benefits of being based here—everything from a publicly educated workforce to an excellent communications infrastructure to a reliable patent system—without adequately paying to support them.”
The two wealth-extracting techniques go together, very often. This is what modern capitalism is increasingly becoming.
Why doesn’t Pfizer’s leadership focus on what it was originally set up to do: wealth creation? And don’t get us started on shareholder value.
Related articles

UN tax convention hub – updates & resources
Submission to Workstream I on Co-Lead’s Zero Draft of UN Framework Convention on International Tax Cooperation (post-Fifth Session)
28 August 2026
Submission to Workstream II on Taxation of Income from Cross-Border Services (post-Fifth Session)
26 August 2026
Strengthening public resource mobilization through tax justice
25 August 2026
Submission to Workstream III on Dispute Prevention and Resolution (post-Fifth Session)
24 August 2026

From data to policy: Building Africa’s evidence ecosystem for better tax reform

New IMF AML Guidance pushes for beneficial ownership transparency and tackles risks from major financial centres

When measurement is political: Accounting for natural resources and the true location of sales under unitary taxation
A 500-billion-dollar decision for the world: the revenue impacts of global unitary taxation
2 August 2026
Detecting Profit Shifting in Administrative Data: A South African Perspective
28 July 2026
